AGIO vs CUBE · rev $36.5M vs P/E 25, rev $1.07B
Agios Pharm (AGIO) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Agios Pharm (AGIO) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported AGIO revenue for 2024-12-31 was $36.5M. Net income was $673.7M. Revenue was up 36.1% from 2023-12-31 to 2024-12-31. AGIO currently screens at market cap $1.68B.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
AGIO currently screens at market cap $1.68B. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the AGIO and CUBE stock pages for the full models.
Not investment advice.